Table 4.
Patient demographics and disease characteristics
| Cohort A (n = 218) | Cohort B (n = 26) | Cohort C (n = 111) | Overall (n = 355) | |
|---|---|---|---|---|
| Median age, years | 64 | 61 | 61 | 63 |
| Family history, breast/ovarian cancer, n (%) | 35 (16) | 3 (12) | 29 (26) | 67 (19) |
| ECOG performance status, n (%) | ||||
| 0–1 | 168 (77) | 26 (100) | 94 (85) | 288 (81) |
| 2–4 | 44 (20) | 0 | 17 (15) | 61 (17) |
| Missing | 6 (3) | 0 | 0 | 6 (2) |
| AJCC stage grouping, n (%) | ||||
| IIIA | 41 (19) | 4 (15) | 16 (14) | 61 (17) |
| IV | 146 (67) | 22 (85) | 70 (63) | 238 (67) |
| PgR-positive status, n (%)a | 155 (71) | 19 (73) | 69 (62) | 243 (68) |
| Tumor proliferation, n (%)a | ||||
| Ki-67 status <20 % | 26 (12) | 2 (8) | 20 (18) | 48 (14) |
| Grade 3 | 100 (46) | 11 (42) | 53 (48) | 164 (46) |
| Metastatic site, n (%) | ||||
| Brain | 6 (3) | 0 | 13 (12) | 19 (5) |
| Lung | 72 (33) | 6 (23) | 36 (32) | 114 (32) |
| Liver | 61 (28) | 3 (12) | 52 (47) | 116 (33) |
| Bone | 118 (54) | 22 (85) | 60 (54) | 200 (56) |
Abbreviations: AJCC American Joint Committee on Cancer, ECOG Eastern Cooperative Oncology Group, PgR progesterone receptor
aMay reflect baseline characteristics before advanced breast cancer (ABC) diagnosis when biopsy was not conducted at ABC diagnosis